Abstract
Purpose
The purpose of this study is to review the literature examining how the beliefs and behaviours of physicians and patients influence clinical communication, doctor–patient interaction and treatment decisions for lung cancer treatment.
Methods
Literature was obtained via electronic database searches and hand searching of journals from 1990 to 2011.
Results
Wide variability in perceptions of the value of chemotherapy in lung cancer is present among both physicians and patients. There is a mismatch in the degree patients and physicians weigh survival, such that patients value survival benefits highly whilst physicians strongly emphasize toxicity and associated symptoms. This lack of congruence between patients and clinicians is influenced by a range of factors and has implications for treatment decisions, long-term survival and quality of life in people affected by lung cancer.
Conclusion
The divergence of treatment priorities indicates a need for improved communication strategies addressing the needs and concerns of both patients and clinicians. Patients should understand the benefits and risks of treatment options, while clinicians can gain a greater awareness of factors influencing patients’ decisions on treatments. Reflecting these perspectives and patient preferences for lung cancer treatment in clinical guidelines may improve clinician awareness.
References
Blinman P, Alam M, Duric V, McLachlan SA, Stockler MR (2010) Patients’ preferences for chemotherapy in non-small cell lung cancer: a systematic review. Lung Cancer 69:141–147
Bremnes RM, Andersen K, Wist EA (1995) Cancer patients, doctors and nurses vary in their willingness to undertake cancer chemotherapy. Eur J Cancer 31:1955–1959
Brundage MD, Davidson JR, Mackillop WJ (1997) Trading treatment toxicity for survival in locally advanced non-small cell lung cancer. J Clin Oncol 15:330
Brundage MD, Feldman-Stewart D, Cosby R, Gregg R, Dixon P, Youssef Y, Mackillop WJ (2001) Cancer patients’ attitudes toward treatment options for advanced non-small cell lung cancer: implications for patient education and decision support. Patient Educ Couns 45:149–157
Chu DT, Kim SW, Kuo HP, Ozacar R, Salajka F, Krishnamurthy S, Damyanov D, Altug S, Reece WHH, Wang L (2007) Patient attitudes towards chemotherapy as assessed by patient versus physician: a prospective observational study in advanced non-small cell lung cancer. Lung Cancer 56:433–443
Clayton JM, Hancock KM, Butow PN, Tattersall M, Currow DC (2007) Clinical practice guidelines for communicating prognosis and end-of-life issues with adults in the advanced stages of a life-limiting illness, and their caregivers. Med J Aust 186:S83–S108
Cleeland CS (2007) Symptom burden: multiple symptoms and their impact as patient-reported outcomes. JNCI Monogr 2007:16
Davidson JR, Brundage MD, Feldman-Stewart D (1999) Lung cancer treatment decisions: patient’s desires for participation and information. Psycho Oncol 8:511–520
Davis TC, Williams MV, Marin E, Parker RM, Glass J (2002) Health literacy and cancer communication. CA Cancer J Clin 52:134–149
Earle CC, Venditti LN, Neumann PJ, Gelber RD, Weinstein MC, Potosky AL, Weeks JC (2000) Who gets chemotherapy for metastatic lung cancer? Chest 117:1239–1246
Efficace F, Bottomley A, Smit EF, Lianes P, Legrand C, Debruyne C, Schramel F, Smit HJ, Gaafar R, Biesma B, Manegold C, Coens C, Giaccone G, Van Meerbeeck J (2006) Is a patient’s self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975. Ann Oncol 17:1698–1704
Fleissig A, Jenkins V, Catt S, Fallowfield L (2006) Multidisciplinary teams in cancer care: are they effective in the UK? Lancet Oncol 7:935–943
Gattellari M, Voigt KJ, Butow PN, Tattersall MHN (2002) When the treatment goal is not cure: are cancer patients equipped to make informed decisions? J Clin Oncol 20:503
Hirose T, Yamaoka T, Ohnishi T, Sugiyama T, Kusumoto S, Shirai T, Okuda K, Ohmori T, Adachi M (2009) Patient willingness to undergo chemotherapy and thoracic radiotherapy for locally advanced non-small cell lung cancer. Psycho Oncol 18:483–489
Jacob S, Hovey E, Ng W, Vinod S, Delaney G, Barton M (2010) Estimation of an optimal chemotherapy utilisation rate for lung cancer: an evidence-based benchmark for cancer care. Lung Cancer 69:307–314
Jansen SJT, Otten W, Stiggelbout AM (2004) Review of determinants of patients’ preferences for adjuvant therapy in cancer. J Clin Oncol 22:3181
Jennens RR, de Boer R, Irving L, Ball DL, Rosenthal MA (2004) Differences of opinion: a survey of knowledge and bias among clinicians regarding the role of chemotherapy in metastatic non-small cell lung cancer. Chest 126:1985–1993
Ko C, Chaudhry S (2002) The need for a multidisciplinary approach to cancer care. J Surg Res 105:53–57
Koedoot CG, De Haan RJ, Stiggelbout AM, Stalmeier PFM, De Graeff A, Bakker PJM, de Haes J (2003) Palliative chemotherapy or best supportive care? A prospective study explaining patients’ treatment preference and choice. Br J Cancer 89:2219–2226
Levinson W, Lesser CS, Epstein RM (2010) Developing physician communication skills for patient-centered care. Health Aff 29:1310–1318
Matsuyama R, Reddy S, Smith TJ (2006) Why do patients choose chemotherapy near the end of life? A review of the perspective of those facing death from cancer. J Clin Oncol 24:3490
Meropol NJ, Weinfurt KP, Burnett CB, Balshem A, Benson Iii AB, Castel L, Corbett S, Diefenbach M, Gaskin D, Li Y (2003) Perceptions of patients and physicians regarding phase I cancer clinical trials: implications for physician-patient communication. J Clin Oncol 21:2589
Montazeri A, Milroy R, Hole D, McEwen J, Gillis CR (2001) Quality of life in lung cancer patients: an important prognostic factor. Lung Cancer 31:233–240
Patel N, Adatia R, Mellemgaard A, Jack R, Moller H (2007) Variation in the use of chemotherapy in lung cancer. Br J Cancer 96:886–890
Perez EA (1998) Perceptions of prognosis, treatment, and treatment impact on prognosis in non-small cell lung cancer. Chest 114:593–604
Raby B, Pater J, Mackillop WJ (1995) Does knowledge guide practice? Another look at the management of non-small-cell lung cancer. J Clin Oncol 13:1904
Richardson GE, Thursfield VJ, Giles GG (2000) Reported management of lung cancer in Victoria in 1993: comparison with best practice. Anti-Cancer Council of Victoria Lung Cancer Study Group. Med J Aust 172:321
Ruhnke GW, Wilson SR, Akamatsu T, Kinoue T, Takashima Y, Goldstein MK, Koenig BA, Hornberger JC, Raffin TA (2000) Ethical decision making and patient autonomy*. Chest 118:1172
Schroen AT, Detterbeck FC, Crawford R, Rivera MP, Socinski MA (2000) Beliefs among pulmonologists and thoracic surgeons in the therapeutic approach to non-small cell lung cancer. Chest 118:129–137
Silvestri G, Pritchard R, Welch HG (1998) Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews. Br Med J 317:771
Vinod SK, Hui AC, Esmaili N, Hensley MJ, Barton MB (2004) Comparison of patterns of care in lung cancer in three area health services in New South Wales Australia. Intern Med J 34:677–683
Vinod SK, O’Connell DL, Simonella L, Delaney GP, Boyer M, Peters M, Miller D, Supramaniam R, McCawley L, Armstrong B (2008) Gaps in optimal care for lung cancer. J Thorac Oncol 3:871
Wan-Chow-Wah D, Monette J, Monette M, Sourial N, Retornaz F, Batist G, Puts MTE, Bergman H (2011) Difficulties in decision making regarding chemotherapy for older cancer patients: a census of cancer physicians. Crit Rev Oncol Hematol 78:45–58
Yardley SJ, Davis CL, Sheldons F (2001) Receiving a diagnosis of lung cancer: patients’ interpretations, perceptions and perspectives. Palliat Med 15:379–386
Yellen SB, Cella DF (1995) Someone to live for: social well-being, parenthood status, and decision-making in oncology. J Clin Oncol 13:1255
Zhang AY, Zyzanski SJ, Siminoff LA (2010) Differential patient-caregiver opinions of treatment and care for advanced lung cancer patients. Soc Sci Med 70:1155–1158
Acknowledgments
This paper is part of a larger project titled Lung Cancer in Australia: Review of the Evidence, Consultation & Research. This project received funding from the Australian Government through Cancer Australia. Dr. DiGiacomo is a postdoctoral fellow supported by NHMRC 533547.
Conflict of interest
The authors have no conflicts of interest to declare other than funding received from Cancer Australia.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Davidson, P.M., Jiwa, M., Goldsmith, A.J. et al. Decisions for lung cancer chemotherapy: the influence of physician and patient factors. Support Care Cancer 19, 1261–1266 (2011). https://doi.org/10.1007/s00520-011-1176-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-011-1176-y